Anixa doses first patient in third cohort of Phase 1 clinical trial of CAR-T

Anixa Biosciences (ANIX) announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell, or CAR-T, therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center. The fourth cohort is expected to commence after a 30-day verification that there continue to be no adverse effects experienced by the third cohort. The third cohort in the trial received a dose of one million CAR-positive cells per kilogram of patient weight, which represents a tenfold increase compared to the first cohort. This escalation is an important step in evaluating the safety and efficacy of CAR-T therapy for ovarian cancer patients. The fourth cohort will increase the dosage by another factor of three. Anixa’s FSHR-mediated CAR-T technology targets the follicle-stimulating hormone receptor, which research indicates is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells. The first-in-human trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.